Viral/Nonviral Chimeric Nanoparticles to Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing

ACS Nano

Volumn 10, Issue 9, 2016, Pages 8705-8714

  Hong, Cheol Am ^a   Cho, Soo Kyung ^b   Edson, Julius A ^b   Kim, Jane ^a   Ingato, Dominique ^b   Pham, Bryan ^a   Chuang, Anthony ^c   Fruman, David A ^a   Kwon, Young Jik ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California at Irvine   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AAV transduction; BIM expression; core shell nanoparticles; hybrid vector; MCL 1 silencing; RNA interference; synergistic leukemia gene therapy

Indexed keywords

AMINO ACIDS; BACTERIOPHAGES; BODY FLUIDS; DISEASES; GENE EXPRESSION; GENE TRANSFER; GENES; NANOPARTICLES; PROTEINS; RNA; VIRUSES;

AAV TRANSDUCTION; BIM EXPRESSION; CORE-SHELL NANOPARTICLES; HYBRID VECTORS; MCL-1 SILENCING; RNA INTERFERENCE;

GENE THERAPY;

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; NANOPARTICLE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; K-562 CELL LINE; LEUKEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE SILENCING; GENETIC THERAPY; HUMANS; K562 CELLS; LEUKEMIA; NANOPARTICLES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TRANSDUCTION, GENETIC;

EID: 84989209094     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.6b04155     Document Type: Article

References (46)

1. McAllister, S. S.; Weinberg, R. A. The Tumour-Induced Systemic Environment as a Critical Regulator of Cancer Progression and Metastasis Nat. Cell Biol. 2014, 16, 717-727 10.1038/ncb3015
2. Wang, R. A.; Li, Q. L.; Li, Z. S.; Zheng, P. J.; Zhang, H. Z.; Huang, X. F.; Chi, S. M.; Yang, A. G.; Cui, R. Apoptosis Drives Cancer Cells Proliferate and Metastasize J. Cell Mol. Med. 2013, 17, 205-211 10.1111/j.1582-4934.2012.01663.x
3. Bignell, G. R.; Greenman, C. D.; Davies, H.; Butler, A. P.; Edkins, S.; Andrews, J. M.; Buck, G.; Chen, L.; Beare, D.; Latimer, C.; Widaa, S.; Hinton, J.; Fahey, C.; Fu, B.; Swamy, S.; Dalgliesh, G. L.; Teh, B. T.; Deloukas, P.; Yang, F.; Campbell, P. J. et al. Signatures of Mutation and Selection in the Cancer Genome Nature 2010, 463, 893-898 10.1038/nature08768
4. Gschwind, A.; Fischer, O. M.; Ullrich, A. The Discovery of Receptor Tyrosine Kinases: Targets for Cancer Therapy Nat. Rev. Cancer 2004, 4, 361-370 10.1038/nrc1360
5. Krause, D. S.; Van Etten, R. A. Tyrosine Kinases as Targets for Cancer Therapy N. Engl. J. Med. 2005, 353, 172-187 10.1056/NEJMra044389
6. Balabanov, S.; Braig, M.; Brümmendorf, T. H. Current Aspects in Resistance Against Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Drug Discovery Today: Technol. 2014, 11, 89-99 10.1016/j.ddtec.2014.03.003
7. An, X.; Tiwari, A. K.; Sun, Y.; Ding, P. R.; Ashby, C. R., Jr.; Chen, Z. S. BCR-ABL Tyrosine Kinase Inhibitors in the Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia: A review Leuk. Res. 2010, 34, 1255-1268 10.1016/j.leukres.2010.04.016
8. Notta, F.; Mullighan, C. G.; Wang, J. C.; Poeppl, A.; Doulatov, S.; Phillips, L. A.; Ma, J.; Minden, M. D.; Downing, J. R.; Dick, J. E. Evolution of Human BCR-ABL1 Lymphoblastic Leukemia-Initiating Cells Nature 2011, 469, 362-367 10.1038/nature09733
9. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N. Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products Science 1990, 247, 1079-1082 10.1126/science.2408149
10. Deininger, M. W. N.; Goldman, J. M.; Melo, J. V. The Molecular Biology of Chronic Myeloid Leukemia Blood 2000, 96, 3343-3356
11. Laurent, E.; Talpaz, M.; Kantarjin, H.; Kurzrock, R. The BCR Gene and Philadelphia Chromosome-Positive Leukemogenesis Cancer Res. 2001, 61, 2345-2355
12. Shet, A. S.; Jahagirdar, B. N.; Verfaillie, C. M. Chronic Myelogenous Leukemia: Mechanisms Underlying Disease Progression Leukemia 2002, 16, 1402-1411 10.1038/sj.leu.2402577
13. Daley, G. Q.; Van Etten, R. A.; Baltimore, D. Induction of Chronic Myelogenous Leukemia in Mice by the P210bcr/abl Gene of the Philadelphia Chromosome Science 1990, 247, 824-830 10.1126/science.2406902
14. Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype Blood 1996, 88, 2375-2384
15. Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; Capdeville, R.; Talpaz, M. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome N. Engl. J. Med. 2001, 344, 1038-1042 10.1056/NEJM200104053441402
16. Cohen, M. H.; Williams, G.; Johnson, J. R.; Duan, J.; Gobburu, J.; Rahman, A.; Benson, K.; Leighton, J.; Kim, S. K.; Wood, R.; Rothmann, M.; Chen, G.; U, K. M.; Staten, A. M.; Pazdur, R. Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia Clin. Cancer Res. 2002, 8, 935-942
17. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia N. Engl. J. Med. 2001, 344, 1031-1037 10.1056/NEJM200104053441401
18. Mohamed, A. N.; Pemberton, P.; Zonder, J.; Schiffer, C. A. The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations Clin. Cancer Res. 2003, 9, 1333-1337
19. Roeder, I.; Horn, M.; Glauche, I.; Hochhaus, A.; Mueller, M. C.; Loeffler, M. Dynamic Modeling of Imatinib-Treated Chronic Myeloid Leukemia: Functional Insights and Clinical Implications Nat. Med. 2006, 12, 1181-1184 10.1038/nm1487
20. Soverini, S.; Hochhaus, A.; Nicolini, F. E.; Gruber, F.; Lange, T.; Saglio, G.; Pane, F.; Müller, M. C.; Ernst, T.; Rosti, G.; Porkka, K.; Baccarani, M.; Cross, N. C.; Martinelli, G. BCR-ABL Kinase Domain Mutation analysis in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors: Recommendations from an Expert Panel on Behalf of European LeukemiaNet Blood 2011, 118, 1208-1215 10.1182/blood-2010-12-326405
21. Deininger, M. Resistance and Relapse with Imatinib in CML: Causes and Consequences J. Natl. Compr. Cancer Network 2008, 2, 11-21
22. Bixby, D.; Talpaz, M. Seeking the Causes and Solutions to Imatinib-Resistance in Chronic Myeloid Leukemia Leukemia 2011, 25, 7-22 10.1038/leu.2010.238
23. Corbin, A. S.; La Rosée, P.; Stoffregen, E. P.; Druker, B. J.; Deininger, M. W. Several Bcr-Abl Kinase Domain Mutants Associated with Imatinib Mesylate Resistance Remain Sensitive to Imatinib Blood 2003, 101, 4611-4614 10.1182/blood-2002-12-3659
24. He, B. L.; Shi, X.; Man, C. H.; Ma, A. C.; Ekker, S. C.; Chow, H. C.; So, C. W.; Choi, W. W.; Zhang, W.; Zhang, Y.; Leung, A. Y. Functions of flt3 in Zebrafish Hematopoiesis and its Relevance to Human Acute Myeloid Leukemia Blood 2014, 123, 2518-2529 10.1182/blood-2013-02-486688
25. Kindler, T.; Lipka, D. B.; Fischer, T. FLT3 as a Therapeutic Target in AML: Still Challenging After All These Years Blood 2010, 116, 5089-5102 10.1182/blood-2010-04-261867
26. O'Hare, T.; Deininger, M. W.; Eide, C. A.; Clackson, T.; Druker, B. J. Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia Clin. Cancer Res. 2011, 17, 212-221 10.1158/1078-0432.CCR-09-3314
27. Li, Q.; Wu, Y.; Fang, S.; Wang, L.; Qi, H.; Zhang, Y.; Zhang, J.; Li, W. BCR/ABL Oncogene-Induced PI3K Signaling Pathway Leads to Chronic Myeloid Leukemia Pathogenesis by Impairing Immuno-Modulatory Function of Hemangioblasts Cancer Gene Ther. 2015, 22, 227-237 10.1038/cgt.2014.65
28. Koldehoff, M.; Zakrzewski, J. L.; Beelen, D. W.; Elmaagacli, A. H. Additive Antileukemia Effects by GFI1B- and BCR-ABL-Specific siRNA in Advanced Phase Chronic Myeloid Leukemic Cells Cancer Gene Ther. 2013, 20, 421-427 10.1038/cgt.2013.31
29. Kuribara, R.; Honda, H.; Matsui, H.; Shinjyo, T.; Inukai, T.; Sugita, K.; Nakazawa, S.; Hirai, H.; Ozawa, K.; Inaba, T. Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hepatopoietic Progenitors Mol. Cell. Biol. 2004, 24, 6172-6183 10.1128/MCB.24.14.6172-6183.2004
30. Essafi, A.; Fernández de Mattos, S.; Hassen, Y. A.; Soeiro, I.; Mufti, G. J.; Thomas, N. S.; Medema, R. H.; Lam, E. W. Direct Transciptional Regulation of Bim by FoxO3a Mediates STI571-Induced Apoptosis in Bcr-Abl-Expressing Cells Oncogene 2005, 24, 2317-2329 10.1038/sj.onc.1208421
31. Koss, B.; Morrison, J.; Perciavalle, R. M.; Singh, H.; Rehg, J. E.; Williams, R. T.; Opferman, J. T. Requirement for Antiapoptotic MCL-1 in the Survival of BCR-ABL B-Lineage Acute Lymphoblastic Leukemia Blood 2013, 122, 1587-1598 10.1182/blood-2012-06-440230
32. Perciavalle, R. M.; Stewart, D. P.; Koss, B.; Lynch, J.; Milasta, S.; Bathina, M.; Temirov, J.; Cleland, M. M.; Pelletier, S.; Schuetz, J. D.; Youle, R. J.; Green, D. R.; Opferman, J. T. Anti-Apoptotic MCL-1 Localizes to the Mitochondrial Matrix and Couples Mitochondria Fusion to Respiration Nat. Cell Biol. 2012, 14, 575-583 10.1038/ncb2488
33. Han, J.; Goldstein, L. A.; Gastman, B. R.; Rabinowich, H. Interrelated Roles for MCL-1 and BIM in Regulation of TRAIL-Mediated Mitochondrial Apoptosis J. Biol. Chem. 2006, 281, 10153-10163 10.1074/jbc.M510349200
34. Cho, S. K.; Pedram, A.; Levin, E. R.; Kwon, Y. J. Acid-Degradable Core-Shell Nanoparticles for Reversed Tamoxifen-Resistance in Breast Cancer by Silencing Manganese Superoxide Dismutase (MnSOD) Biomaterials 2013, 34, 10228-10237 10.1016/j.biomaterials.2013.09.003
35. Benskey, M. J.; Kuhn, N. C.; Galligan, J. J.; Garcia, J.; Boye, S. E.; Hauswirth, W. W.; Mueller, C.; Boye, S. L.; Manfredsson, F. P. Targeted Gene Delivery to the Enteric Nervous System Using AAV: a Comparison Across Serotypes and Capsid Mutants Mol. Ther. 2015, 23, 488-500 10.1038/mt.2015.7
36. Mingozzi, F.; High, K. A. Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy Blood 2013, 122, 23-36 10.1182/blood-2013-01-306647
37. Nathwani, A. C.; Tuddenham, E. G.; Rangarajan, S.; Rosales, C.; McIntosh, J.; Linch, D. C.; Chowdary, P.; Riddell, A.; Pie, A. J.; Harrington, C.; O'Beirne, J.; Smith, K.; Pasi, J.; Glader, B.; Rustagi, P.; Ng, C. Y.; Kay, M. A.; Zhou, J.; Spence, Y.; Morton, C. L. et al. Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B N. Engl. J. Med. 2011, 365, 2357-2365 10.1056/NEJMoa1108046
38. Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery Materials for siRNA Therapeutics Nat. Mater. 2013, 12, 967-977 10.1038/nmat3765
39. Cho, S. K.; Kwon, Y. J. Simultaneous Gene Transduction and Silencing Using Stimuli-Responsive Viral/Nonviral Chimeric Nanoparticles Biomaterials 2012, 33, 3316-3323 10.1016/j.biomaterials.2012.01.027
40. Jørgensen, H. G.; Allan, E. K.; Jiang, X.; Liakopoulou, E.; Richmond, L.; Eaves, C. J.; Eaves, A. C.; Holyoake, T. L. Stage-Specific Alterations in Serum Levels of G-CSF in Chronic Myeloid Leukaemia Leukemia 2003, 17, 1430-1432 10.1038/sj.leu.2402967
41. Hong, C. A.; Nam, Y. S. Functional Nanostructures for Effective Delivery of Small Interfering RNA Therapeutics Theranostics 2014, 4, 1211-1232 10.7150/thno.8491
42. Mingozzi, F.; High, K. A. Therapeutic in vivo Gene Transfer for Genetic Disease Using AAV: Progress and Challenges Nat. Rev. Genet. 2011, 12, 341-355 10.1038/nrg2988
43. Lowenstein, P. R.; Mandel, R. J.; Xiong, W. D.; Kroeger, K.; Castro, M. G. Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: the Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions Curr. Gene Ther. 2007, 7, 347-360 10.2174/156652307782151498
44. Kreppel, F.; Kochanek, S. Modification of Adenovirus Gene Transfer Vectors with Synthetic Polymers: a Scientific Review and Technical Guide Mol. Ther. 2008, 16, 16-29 10.1038/sj.mt.6300321
45. Kim, P. H.; Kim, T. I.; Yockman, J. W.; Kim, S. W.; Yun, C. O. The Effect of Surface Modification of Adenovirus with an Arginine-Grafted Bioreducible polymer on Transduction Efficiency and Immunogenicity in Cancer Gene Therapy Biomaterials 2010, 31, 1865-1874 10.1016/j.biomaterials.2009.11.043
46. Kotterman, M. A.; Yin, L.; Strazzeri, J. M.; Flannery, J. G.; Merigan, W. H.; Schaffer, D. V. Antibody Neutralization Poses a Barrier to Intravitreal Adeno-Associated Viral Vector Gene Delivery to Non-Human Primates Gene Ther. 2015, 22, 116-126 10.1038/gt.2014.115